Dyne Therapeutics/$DYN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Dyne Therapeutics
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
Ticker
$DYN
Sector
Primary listing
Employees
263
Headquarters
Website
DYN Metrics
BasicAdvanced
$4.7bn
-
-$3.35
-
-
Price and volume
Market cap
$4.7bn
52-week high
$26.26
52-week low
$9.57
Average daily volume
2.7m
Financial strength
Current ratio
12.02
Quick ratio
11.515
Long term debt to equity
30.454
Total debt to equity
31.218
Interest coverage (TTM)
-36.05%
Profitability
EBITDA (TTM)
-534.805
Management effectiveness
Return on assets (TTM)
-38.96%
Return on equity (TTM)
-81.57%
Valuation
Price to book
5.94
Price to tangible book (TTM)
5.94
Price to free cash flow (TTM)
-7.824
Free cash flow yield (TTM)
-12.78%
Free cash flow per share (TTM)
-3.218
Growth
Earnings per share change (TTM)
-13.46%
3-year earnings per share growth (CAGR)
-0.79%
What the Analysts think about DYN
Analyst ratings (Buy, Hold, Sell) for Dyne Therapeutics stock.
DYN Financial Performance
Revenues and expenses
DYN Earnings Performance
Company profitability
DYN News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.